Brief: NewAmsterdam Pharma Completes Enrollment In Late-Stage Study Of Heart Disease Treatment
25/07/2023 22:12
July 25 (Reuters) - NewAmsterdam Pharma Company NV
NAMS.O :
* NEWAMSTERDAM PHARMA COMPLETES ENROLLMENT IN PIVOTAL PHASE
3
BROADWAY CLINICAL TRIAL EVALUATING OBICETRAPIB IN PATIENTS WITH
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND/OR ESTABLISHED
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
* NEWAMSTERDAM PHARMA COMPANY NV - TOPLINE RESULTS EXPECTED
IN 2H
2024
* NEWAMSTERDAM PHARMA COMPANY NV - DOUBLE-BLIND,
PLACEBO-CONTROLLED PHASE 3 BROADWAY TRIAL ALSO EVALUATING SAFETY
AND TOLERABILITY OF OBICETRAPIB
Source text for Eikon: ID:nGNXccFV4H
Further company coverage: NAMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)